Analyst firms · Morgan Stanley · MRK

Morgan Stanley MRK price target and rating history

Merck & Company Inc. (MRK) · Health Care

Morgan Stanley rates Merck & Company Inc. (MRK) Overweight with a $179 price target, as of its latest action on Aug 20, 2026. It has published 6 rating actions on MRK since September 2021, including 1 upgrade and 1 downgrade. Across 10 firms with a MRK price target in the last 12 months, the median target is $141.50. Morgan Stanley's $179 is 27% above that.

Current rating
Overweight
Price target
$179
Median target, all firms
$141.50
Actions on MRK
6

Morgan Stanley price target on MRK

$179$130$8020222023202420252026
Morgan Stanley price target on MRK, each point a stated target, September 2021 to August 2026.

Every Morgan Stanley rating on MRK

How other firms rate MRK

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
DZ BankHold$153Nov 3, 2026
RBC Capital MarketsSector Perform$150Aug 20, 2026
Morgan StanleyOverweight$179Aug 20, 2026
DaiwaOutperform$143Aug 12, 2026
CitigroupNeutral$125May 6, 2026
BarclaysOverweight$140Feb 20, 2026
Deutsche BankBuy$150Feb 13, 2026
Wolfe ResearchOutperform$135Jan 8, 2026
BMO Capital MarketsOutperform$130Dec 18, 2025
Wells FargoOverweight$125Nov 24, 2025

Questions about Morgan Stanley and MRK

What is Morgan Stanley's price target for MRK?
Morgan Stanley's latest stated price target for Merck & Company Inc. (MRK) is $179, from its action on Aug 20, 2026.
What is Morgan Stanley's rating on MRK?
Morgan Stanley rates MRK Overweight, a bullish rating, as of Aug 20, 2026.
When did Morgan Stanley last change its view on MRK?
On Aug 20, 2026, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $179.
How does Morgan Stanley's MRK target compare with other analysts?
Across 10 firms with a MRK price target in the last 12 months, the median target is $141.50. Morgan Stanley's $179 is 27% above that.

More MRK rating histories

All Morgan Stanley ratingsMRK news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.